WHEN NAVIGATING THE DIFFICULTIES OF MULTIPLE MYELOMA IN THE REAL WORLD, YOU NEED

DURABLE STRENGTH

THE NINLARO^® (ixazomib) REGIMEN* OFFERS EXTENDED EFFICACY AND MANAGEABLE TOLERABILITY FOR THE TYPES OF PATIENTS YOU SEE EVERY DAY^1-6

LEADING THE WAY TO
EXTENDED EFFICACY
SAFETY
INFORMATION

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
^*The NINLARO regimen includes NINLARO+lenalidomide+dexamethasone.

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
^*The NINLARO regimen includes NINLARO+lenalidomide+dexamethasone.

Expert Insights

See what Dr. Vescio has to say about multiple myeloma and the NINLARO treatment regimen.

Watch now

Dr. Vescio is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Takeda Oncology Patient Support Program

Your connection for coverage support, financial assistance, and educational resources.

Enrollment Form

Dr. Vescio is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.